This Government Contract opportunity from Department Of Veterans Affairs was posted on June 1, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Supply of XOFIGO® (Radium-223 dichloride) Radiopharmaceutical

Closed

Federal

Submission Closed06/08/2026, 08:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

DIBBS

METOPROLOL TARTRATEThe contract pertains to the procurement of Metoprolol Tartrate, identified by the National Stock Number 6505-01-615-1537, with a requested quantity of one unit under purchase request number 7017142424. The solicitation, numbered SPE2DP-26-T-3815, was posted by the Defense Logistics Agency, a branch of the Department of Defense, on June 16, 2026. The deadline for responses to this solicitation is June 22, 2026, indicating a brief window for bid submissions. This contract is categorized as a solicitation from a federal agency, with no specified type of set-aside or NAICS code provided. The place of performance and office location details are unspecified beyond being within the United States. The solicitation is accessible through the Defense Logistics Agency’s bidding system, and it appears focused on securing this specific pharmaceutical item for defense-related use.

Defense Logistics Agency

POSTED

DEADLINE

Supply of QIAamp Viral RNA Mini KitsThe contract involves the supply of eight kits specifically designed for viral RNA extraction from clinical samples, identified as QIAamp Viral RNA Mini Kits. Issued by the U.S. Embassy in Tbilisi under the Department of State, this subcontract is categorized under the NAICS code 325412, which pertains to pharmaceutical preparation manufacturing. The procurement process was initiated on June 16, 2026, with a response deadline set for July 6, 2026. The performance location for delivery is in Tbilisi, with a designated postal code of 0186. This contracting opportunity does not specify a solicitation number, type of set-aside, or further details on organization type or points of contact. It is a straightforward supply contract aimed at equipping the designated facility in Tbilisi with essential kits for viral RNA extraction, which are critical for clinical diagnostics and research related to viral pathogens. The contract is accessible through a dedicated link on the federal contracting platform, indicating transparency and open competition in the procurement process.

POSTED

DEADLINE

Wound Infection Prevention & Sepsis Countermeasure DevelopmentThe contract involves the development of a drug/device combination product aimed at preventing or treating wound infections and sepsis specifically in battlefield or austere environments. The project is targeted to advance this product to Phase I clinical trials under the FDA 505(b)(2) regulatory pathway, which facilitates the approval process by leveraging existing data. This effort is intended to address critical medical needs encountered by military personnel in challenging settings, ensuring rapid and effective countermeasures against potentially life-threatening infections. Issued by the Army Medical Resources Acquisition Activity under the Department of Defense, the contract is a subcontract with a focus on the pharmaceutical manufacturing sector (NAICS code 325412). The work will be performed in Frederick, capturing the strategic importance of this location for medical research and development. The solicitation was posted on June 16, 2026, with a response deadline of July 17, 2026, highlighting a clear and concise timeline for interested parties. This project underscores a high-priority initiative to enhance battlefield medical capabilities through innovative therapeutic solutions.

Army Medical Resources Acq Activity

POSTED

DEADLINE

Supply of Diagnostic PCR Kits (Zika, Dengue, Chikungunya)This contract involves the supply of one kit of the VIASURE Real-Time PCR Kit designed for the simultaneous detection of Zika, Dengue, and Chikungunya viruses. The contract is a subcontract opportunity posted by the US Embassy in Tbilisi under the Department of State. The solicitation was made public on June 16, 2026, with a response deadline set for July 6, 2026. The contract falls under the NAICS code 325412, indicating it pertains to pharmaceutical preparation manufacturing. The kit is intended for use in Tbilisi, Georgia, and aims to facilitate efficient diagnostic testing for these three viruses in a single assay. This opportunity does not specify any set-aside requirements, and detailed contact information is not provided. The purpose is to enhance diagnostic capabilities in the region through timely and reliable detection of these mosquito-borne illnesses.

POSTED

DEADLINE

Supply of COPAN UTM RT 3ML Collection SystemsThe contract involves the supply of 300 packets of COPAN UTM RT 3ML collection systems without applicators, intended for specimen collection and transport. This procurement is structured as a subcontract and falls under the NAICS code 325412, indicating its classification within pharmaceutical preparation manufacturing. The contract is issued by the US Embassy in Tbilisi, specifically through the Department of State, with the place of performance set in Tbilisi. The solicitation was posted on June 16, 2026, with a response deadline of July 6, 2026. While there is no designated type of set-aside or specific organization type required for bidders, the procurement is focused on acquiring bulk specimen collection systems without applicators, reflecting a specialized medical supply need. The contract details emphasize timely delivery to the designated location, ensuring the availability of these collection systems for relevant health and research activities overseen by the embassy.

US Embassy Tbilisi

POSTED

2 days ago

DEADLINE

in 19 days

AI Contract Overview

This contract involves the procurement and delivery of 1,000 units of XOFIGO®, a radiopharmaceutical approved by the FDA for treating metastatic castration-resistant prostate cancer with bone metastases. The product must comply with all applicable federal regulations and adhere to the manufacturer’s specifications, ensuring safety and efficacy for patients. The contract is classified under NAICS code 325412 and is issued by the Department of Veterans Affairs through the 257-NETWORK Contract Office 17. The solicitation for this subcontract was posted on June 1, 2026, with a response deadline of June 8, 2026. Although specific details like the solicitation number, set-aside type, and location of performance are not provided, the contract is clearly focused on supplying this specialized drug to meet medical needs within the federal healthcare system. The emphasis on compliance and FDA approval underscores the critical nature of the product in treating a serious form of prostate cancer.

General Info

Procurement and delivery of 1,000 FDA-approved XOFIGO units for metastatic prostate cancer treatment.

Agency

Department Of Veterans Affairs → 257-NETWORK Contract Office 17 (36C257)

NAICS

325412 - Pharmaceutical Preparation Manufacturing View NAICS

Place of Performance

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedJun 1

subcontract

Response DeadlineJun 8

Deadline has passed

Submission Closed

06/08/2026, 08:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Veterans Affairs → 257-NETWORK Contract Office 17 (36C257)

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Veterans Affairs → 257-NETWORK Contract Office 17 (36C257)

Office AddressN/A

ContactsNo contact information available

Full Description

Procurement and delivery of 1,000 units (uCi) of XOFIGO®, an FDA-approved radiopharmaceutical for metastatic castration-resistant prostate cancer with bone metastases, compliant with federal regulations and manufacturer specifications.